Institute of Physiology, Justus Liebig University, 35392 Giessen, Germany.
Biochemical-Pharmacological Centre (BPC) Marburg, Institute of Pharmacology and Clinical Pharmacy, University of Marburg, 35043 Marburg, Germany.
Int J Mol Sci. 2021 Apr 16;22(8):4110. doi: 10.3390/ijms22084110.
Heart failure (HF) and atrial fibrillation (AF) are two major life-threatening diseases worldwide. Causes and mechanisms are incompletely understood, yet current therapies are unable to stop disease progression. In this review, we focus on the contribution of the transcriptional modulator, Jun dimerization protein 2 (JDP2), and on HF and AF development. In recent years, JDP2 has been identified as a potential prognostic marker for HF development after myocardial infarction. This close correlation to the disease development suggests that JDP2 may be involved in initiation and progression of HF as well as in cardiac dysfunction. Although no studies have been done in yet, studies on genetically modified impressively show involvement of JDP2 in HF and AF, making it an interesting therapeutic target.
心力衰竭（HF）和心房颤动（AF）是全球两种主要的危及生命的疾病。其病因和发病机制尚不完全清楚，但目前的治疗方法无法阻止疾病的进展。在这篇综述中，我们重点介绍转录调节剂 Jun 二聚化蛋白 2（JDP2）在 HF 和 AF 发展中的作用。近年来，JDP2 已被确定为心肌梗死后 HF 发展的潜在预后标志物。这种与疾病发展的密切相关性表明，JDP2 可能参与 HF 的发生和发展以及心脏功能障碍。尽管尚未进行研究，但对基因修饰的研究令人印象深刻地表明 JDP2 参与了 HF 和 AF，使其成为一个有趣的治疗靶点。
